• 1
    World Health Organization. Preventing chronic diseases: a vital investment. WHO Global Report. 2005. URL:
  • 2
    Seibold J. Scleroderma. In: HarrisE, BuddRC, FiresteinGS, GenoveseMC, SergentJS, RuddyS, et al, editors. Kelley's textbook of rheumatology. 7th ed. Philadelphia: Elsevier; 2005. p. 1279308.
  • 3
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 4
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 5
    Thombs B, Taillefer S, Hudson M, Baron M. Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007; 57: 108997.
  • 6
    Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 163047.
  • 7
    Ware JE Jr, Sherbourne CD. The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 8
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al, and the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 200812.
  • 9
    Khanna D. Health-related quality of life: a primer with a focus on scleroderma. Sclero Care Res 2006; 3: 313.
  • 10
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 11
    Gliddon AE, Dore CJ, Maddison PJ, and the Quins Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006; 55: 4739.
  • 12
    Johnson SR, Gladman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33: 111722.
  • 13
    Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 4854.
  • 14
    Spiegelhalter D, Myles J, Jones D, Abrams K. Bayesian methods in health technology assessment: a review. Health Technol Assess 2000; 4: 1130.
  • 15
    Spiegelhalter DJ, Thomas A, Best NG. WinBUGS: user's manual, version 1.2. Cambridge (UK): MRC Biostatistics Unit; 1999.
  • 16
    R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2007.
  • 17
    R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008. URL:
  • 18
    Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. Stat Sci 1992; 7: 457511.
  • 19
    Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. J Comp Graph Stat 1997; 7: 43455.
  • 20
    Viechtbauer W. MiMa: an S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models. URL:
  • 21
    Sallam H, McNearney TA, Doshi D, Chen JD. Transcutaneous electrical nerve stimulation (TENS) improves upper GI symptoms and balances the sympathovagal activity in scleroderma patients. Dig Dis Sci 2007; 52: 132937.
  • 22
    Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form health survey. Arthritis Rheum 2007; 57: 94102.
  • 23
    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007; 56: 167684.
  • 24
    Khanna D, Park GS, Seibold J. SF-36 scales in the Relaxin study [letter]. Rheumatology (Oxford) 2007; 46: 724.
  • 25
    Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2007; 16: 108392.
  • 26
    Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, et al. Health values of patients with systemic sclerosis. Arthritis Rheum 2007; 57: 8693.
  • 27
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 265566.
  • 28
    Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, et al. Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 1298302.
  • 29
    Sandqvist G, Akesson A, Eklund M. Daily occupations and well-being in women with limited cutaneous systemic sclerosis. Am J Occup Ther 2005; 59: 3907.
  • 30
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 31
    Georges C, Chassany O, Mouthon L, Tiev K, Toledano C, Meyer O, et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005; 24: 310.
  • 32
    Georges C, Chassany O, Mouthon L, Tiev K, Marjanovic Z, Meyer O, et al. Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis. Rev Med Interne 2004; 25: 1621. In French.
  • 33
    Del Rosso A, Boldrini M, D'Agostino D, Placidi GP, Scarpato A, Pignone A, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004; 51: 47581.
  • 34
    Belotti Masserini A, Zeni S, Cossutta R, Soldi A, Fantini F. Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients. Reumatismo 2003; 55: 24555. In Italian.
  • 35
    Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut 2002; 51: 8813.
  • 36
    Kenefick NJ, Vaizey CJ, Cohen RC, Nicholls RJ, Kamm MA. Medium-term results of permanent sacral nerve stimulation for faecal incontinence. Br J Surg 2002; 89: 896901.
  • 37
    Cossutta R, Zeni S, Soldi A, Colombelli P, Belotti Masserini A, Fantini F. Evaluation of quality of life in patients with systemic sclerosis by administering the SF-36 questionnaire. Reumatismo 2002; 54: 1227. In Italian.
  • 38
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 83240.
  • 39
    Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, et al. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology (Oxford) 2006; 45: 9991004.
  • 40
    Postlethwaite AE, Furst DE, Wong WK, Clements P. Oral tolerance (OT) induction to type I collagen (Cl) significantly reduces the skin score in patients with diffuse systemic sclerosis (SSc) with late-phase disease: results of a NIAMS/NIAID multicenter phase II placebo-controlled double blind clinical trial [abstract]. Arthritis Rheum 2005; 52: 4109.
  • 41
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 40715.
  • 42
    Thombs BD, Hudson M, Taillefer SS, Baron M, and the Canadian Scleroderma Research Group. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum 2008; 59: 5049.
  • 43
    Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 224655.
  • 44
    Silman AJ. Scleroderma: demographics and survival. J Rheumatol Suppl 1997; 48: 5861.